Feb 8 | News
THOUSAND OAKS, Calif., Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone ...
|
Feb 8 | News
Amgen will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today's meeting of the U.S. FDA Oncologic Drugs Advisory Committee (ODAC).
|
Feb 7 | News
WASHINGTON (AP) — Scientists for the FDA say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.
|
Jan 27 | News
Amgen Inc. said Thursday that its fourth-quarter profit fell 8.5 percent as its expenses for taxes and for producing and selling drugs rose faster than its revenue.
|
Jan 26 | News
Full Year 2011 GAAP EPS Decreased 16 Percent to $4.04 Due to a One-Time Charge
2012 Total Revenue and Adjusted EPS Expected to be in the Range of $16.1-$16.5 Billion and $5.90-$6.15, Respectively
Amgen reported total revenue increased 3 percent during the fourth quarter of 2011 to...
|
Jan 26 | News
Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies
Micromet’s Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types
All-Cash Transaction Values Micromet at $1.16 Billion
THOUSAND OAKS, Calif., and ROCKVILLE, ...
|
Jan 26 | News
Amgen and Micromet, Inc. today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet ...
|
Jan 24 | News
THOUSAND OAKS, Calif., Jan. 24, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2011 financial results on Thursday, Jan. 26, 2012 after the close of the financial markets. The announcement will be followed by a...
|
Jan 6 | News
THOUSAND OAKS, Calif., Dec. 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental...
|
Jan 6 | News
THOUSAND OAKS, Calif., Jan. 4, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) will present at the 30th Annual J.P. Morgan Global Healthcare Conference at 10:00 a.m. Pacific Time on Monday, Jan. 9, 2012, at the Westin St. Francis in San Francisco, Calif. Robert A. Bradway, president...
|